SAS Output

21-OCT-2018 6:10

MELAN ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1320-Adv, BRAF mut, Inter v Contin 1 Y 1 Lead-in Continuous Dosing 280 224 49 12 5 3 0 09/19/2014 225 99
            224 49 12 5 3 0      
 
    2 Y 2 Continuous Dosing 237 95 23 9 3 1 0 09/19/2014    
        3 Intermittent Dosing   90 19 7 1 0 0      
            185 42 16 4 1 0      
 
  S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro) 1 Y 1 MK-3475 (pembrolizumab) 77 17 14 10 5 3 1 02/06/2017 90 42
            17 14 10 5 3 1      
 
  S1607-MELAN, Adv, T-VEC, MK-3475 1 Y 1 T-VEC + MK-3475(pembrolizumab) 64 5 5 5 3 3 1 06/05/2018 30 18
            5 5 5 3 3 1      
 
  S1616-MELAN, Adv, Ipilimumab Nivolumab 1 Y 1 Ipilimumab 94 8 8 6 1 0 0 10/23/2017 233 94
        2 Nivolumab + Ipilimumab   16 16 10 4 1 1      
            24 24 16 5 1 1      
 
Yes EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T 1 E Total Registrations   30 8 4 4 0 0 11/03/2015 349 141
            30 8 4 4 0 0      
 
    2 E Total Registrations   12 7 5 5 1 0 11/03/2015    
            12 7 5 5 1 0      
 
  EA6141-Melan, Avd, Nivolumab+Ipi Sargmostim 1 E Total Registrations   36 0 0 0 0 0 03/25/2016 314 134
            36 0 0 0 0 0